This paper evaluates whether cystectomy can be safely omitted in select muscle-invasive bladder cancer (MIBC) patients who achieve a clinical complete response (cCR) after neoadjuvant systemic therapy, emphasizing the need for rigorous, standardized response assessment.
Emerging data suggest clinical response assessment can guide individualized (bladder-sparing) treatment decisions in MIBC, but the authors note that uniform assessment protocols and consistent cCR definitions are required before this approach can be broadly adopted.
The abstract does not report specific patient numbers, outcomes data, or a defined study timeframe; conclusions are based on a review of emerging evidence rather than a primary trial. No control comparator group or survival endpoints are provided.
When a MIBC patient achieves cCR after neoadjuvant therapy, bladder-sparing may be a viable individualized option — but only if response is assessed with the same rigor applied to any validated biomarker, using standardized definitions and protocols. Further prospective studies are needed before routine cystectomy omission.
Explore related topics
